

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kessler Paul D.</u> (Last) (First) (Middle) <u>C/O NABI BIOPHARMACEUTICALS</u> <u>12276 WILKINS AVENUE</u> (Street) <u>ROCKVILLE MD 20852</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/21/2008</u>	3. Issuer Name and Ticker or Trading Symbol <u>NABI BIOPHARMACEUTICALS [NABI]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP Clinical, Med. & Reg.; CMO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>44,360</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Option (right to buy)</u>	<u>(1)</u>	<u>03/14/2015</u>	<u>Common Stock</u>	<u>10,000</u>	<u>12.06</u>	<u>D</u>	
<u>Option (right to buy)</u>	<u>(1)</u>	<u>05/16/2015</u>	<u>Common Stock</u>	<u>15,000</u>	<u>11.49</u>	<u>D</u>	
<u>Option (right to buy)</u>	<u>03/01/2009</u>	<u>02/24/2016</u>	<u>Common Stock</u>	<u>20,613</u>	<u>3.83</u>	<u>D</u>	
<u>Option (right to buy)</u>	<u>(2)</u>	<u>05/25/2013</u>	<u>Common Stock</u>	<u>15,000</u>	<u>5.65</u>	<u>D</u>	
<u>Option (right to buy)</u>	<u>(3)</u>	<u>05/18/2014</u>	<u>Common Stock</u>	<u>90,000</u>	<u>5.2</u>	<u>D</u>	

Explanation of Responses:

- The holder of this option may exercise it at any time.
- This option vests in four equal annual installments beginning on May 25, 2007.
- This option vests in four equal annual installments beginning on January 2, 2008.

Remarks:

/s/ James E. Dawson, as
attorney-in-fact03/03/2008

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.